Promegestone
From Wikipedia, the free encyclopedia
Jump to: navigation, search
 |
|
| Clinical data | |
|---|---|
| ATC code | G03DB07 (WHO) |
| Identifiers | |
|
|
| Synonyms | R-5020; RU-5020 |
| CAS Number | 34184-77-5 |
| PubChem (CID) | 36709 |
| ChemSpider | 33716 |
| KEGG | D08431 |
| ECHA InfoCard | 100.207.681 |
| Chemical and physical data | |
| Formula | C22H30O2 |
| Molar mass | 326.472 g/mol |
| 3D model (Jmol) | Interactive image |
|
|
|
|
Promegestone (INN) (brand name Surgestone), also known as 17α,21-dimethyl-Δ9-19-norprogesterone or 17α,21-dimethyl-19-norpregna-4,9-diene-3,20-dione,[1] is a steroidal progestin of the 19-norprogesterone group which was introduced in 1983 and is marketed in France, Portugal, and Argentina.[1][2][3][4] Indications include gynaecological conditions caused by luteal insufficiency, including premenopausal disorders, dysmenorrhea, and premenstrual syndrome.[4] Promegestone has weak glucocorticoid activity, but does not bind to the androgen receptor or possess antimineralocorticoid activity.[4][5] In addition, promegestone has been found to act as a non-competitive antagonist of the nicotinic acetylcholine receptor, similarly to progesterone.[6] The drug is mainly bound to albumin; it does not bind to sex hormone-binding globulin, and binds only weakly to transcortin.[5]
See also[edit]
- Demegestone
- Gestonorone caproate
- Medrogestone
- Nomegestrol acetate
- ORG-2058
- Segesterone acetate
- Trimegestone
References[edit]
- ^ a b J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 1026–. ISBN 978-1-4757-2085-3.
- ^ William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia, 3rd Edition. Elsevier. pp. 2935–. ISBN 978-0-8155-1856-3.
- ^ Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 883–. ISBN 978-3-88763-075-1.
- ^ a b c Cain (11 September 1984). ANNUAL REPORTS IN MED CHEMISTRY V19 PPR. Academic Press. pp. 323–. ISBN 978-0-08-058363-1.
- ^ a b Kuhl, H (2009). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 (sup1): 3–63. doi:10.1080/13697130500148875. ISSN 1369-7137. PMID 16112947.
- ^ Blanton MP, Xie Y, Dangott LJ, Cohen JB (February 1999). "The steroid promegestone is a noncompetitive antagonist of the Torpedo nicotinic acetylcholine receptor that interacts with the lipid-protein interface". Mol. Pharmacol. 55 (2): 269–78. PMID 9927618.
| PR |
|
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| mPRs (PAQRs) |
|
||||||||||
| GR |
|
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||||
|
|||||||||||||||||
|
|||||||||||||||||
|
|||||||||||||||||
|
|||||||||||||||||
 |
This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |
 |
This article about a steroid is a stub. You can help Wikipedia by expanding it. |
